Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Emergent BioSolutions
The study is closed and all subjects have completed treatment.
The study is to evaluate the safety and efficacy of Humax CD4 with CHO vs CHO alone in subjects with non-cutaneous T cell lymphoma. The primary efficacy will be evaluated by time to relapse.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnostic biopsy of non cutaneous T Cell lymphoma with positive phenotype
Relapsed or refractory to minimum of one course of chemotherapy
Study is closed to enrollment.
Clareo Health | HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma
